Aeterna Zentaris Files Form 6-K
Ticker: CSCIF · Form: 6-K · Filed: Jun 13, 2024 · CIK: 1113423
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Aeterna Zentaris filed a 6-K, standard reporting. Nothing major revealed yet.
AI Summary
Aeterna Zentaris Inc. filed a Form 6-K on June 13, 2024, reporting as a foreign private issuer. The filing includes Exhibit 99.1, but the specific content of this exhibit is not detailed in the provided text. The company is incorporated in A6 and its fiscal year ends on December 31.
Why It Matters
This filing indicates ongoing reporting requirements for Aeterna Zentaris Inc. as a foreign private issuer, which is standard for companies with international operations or listings.
Risk Assessment
Risk Level: low — The filing is a routine report and does not contain information that suggests immediate significant risk or opportunity.
Key Players & Entities
- Aeterna Zentaris Inc. (company) — Filer of the Form 6-K
- Norton Rose Fulbright Canada, LLP (company) — Legal counsel and address for Aeterna Zentaris Inc.
- 20240613 (date) — Filing date of the Form 6-K
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer filed by Aeterna Zentaris Inc. pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of June 2024.
What is the filing date of this report?
The filing date of this report is June 13, 2024.
Does Aeterna Zentaris Inc. file annual reports under Form 20-F or Form 40-F?
Aeterna Zentaris Inc. indicates it files annual reports under Form 20-F.
What is the principal executive office address for Aeterna Zentaris Inc.?
The address of the principal executive office is c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7.
What exhibit is included with this Form 6-K?
Exhibit 99.1 is included with this report on Form 6-K.
Filing Stats: 278 words · 1 min read · ~1 pages · Grade level 11 · Accepted 2024-06-13 09:20:29
Filing Documents
- form6-k.htm (6-K) — 16KB
- ex99-1.htm (EX-99.1) — 21KB
- form6-k_001.jpg (GRAPHIC) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001493152-24-023642.txt ( ) — 61KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-38064 Aeterna Zentaris Inc. (Translation of registrant’s name into English) c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Exhibit 99.1, included with this report on Form 6-K are hereby incorporated by reference into the Registrant’s Registration Statements on Forms S-8 (No. 333-224737, No. 333-210561 and No. 333-200834) and Forms F-3 (No.333-232935 and No. 333-254680) and shall be deemed to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished. DOCUMENTS INDEX Exhibit Description 99.1 Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency (2) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AETERNA ZENTARIS INC. Date: June 13, 2024 By: /s/ Gilles Gagnon Gilles Gagnon President and Chief Executive Officer (3)